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EcoRI restriction fragment length polymorphisms (RFLP) at the human c-mos locus were analysed in DNAs of normal 
individuals and tumour patients. Two alleles with fragment lengths of 2.6 kb (Al) and 5.6 kb (A2) respectively were 
detected. The allele distribution among the tumour group was similar to that of the control group. No difference was 
found between the allele frequencies in leucocytes and tumour tissue DNA of the same patients. 
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1. INTRODUCTION 
A variety of genes are able to transform normal 
fibroblasts into tumour cells [ 1,2]. In the human 
genome such genes - named proto-oncogenes -
exist, which appear to be involved in 
tumourigenesis [3,4] after activation by different 
mechanisms uch as point mutation, translocation, 
amplification or coming under the control of 
specific promoter/enhancer elements 15-71. 
If we assume that somatic mutations are the 
origin of tumoui development [8], the question 
arises as to whether some alleles at oncogene loci 
may be linked to a susceptibility to cancer. Ex- 
amination of RFLP frequencies at the c-s& c-myc, 
c-H~-ras and c-mos loci supports this proposal [9]. 
At the moment the relationship between the occur- 
rence of unique Ha-ras alleles and cancer risk 
assessment is highly controversial. While one 
group [ 10,l l] found an association between rare 
alleles and tumour development, subsequent 
studies did not confirm these results [12-141. 
With respect to c-mos, Lidereau et al. [15] 
reported the occurrence of an EcoRI polymor- 
phism exclusively in the DNA of some breast 
cancer patients. Breast cancer exhibits a hereditary 
component by virtue of its familial aggregation 
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[16]. Analyses of the frequency and tumour 
specificity of oncogene alleles may therefore be a 
useful approach to search for genetic markers in- 
dicating a predisposition to cancer. 
The human DNA sequence c-mos, homologous 
to the transforming gene of the Moloney murine 
sarcoma virus (MO-MSV), is located on 
chromosome 8 [17,18]. So far studies of the 
transforming potential of c-mos showed that the 
gene can only be activated by linkage to the long 
terminal repeat (LTR) of the MO-MSV [19,20]. 
We have studied DNAs from a control group 
and patients with gynaecological tumours and lym- 
phomas. The EcoRI polymorphism was detected in 
non-affected individuals and in DNAs derived 
from various tumour tissues. Their frequency of 
occurrence among tumour patients and controls is 
comparable. This allele does not therefore seem to 
be tumour-specific but it is rare in the general 
population. 
2. MATERIALS AND METHODS 
DNA samples from 140 (80 women, 60 men) normal healthy 
individuals, 75 patients with breast cancer, 46 patients with 
ovarian cancer, 11 patients with cancer of the cervix, 9 patients 
with cancer of the uterus and 15 patients with lymphomas were 
examined. There were no discernible differences in the ethnic 
composition of the control and tumour group. Different types 
of cancer were diagnosed by pathological investigation in the 
clinics. 
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DNA of the control group was extracted from white blood 
cells. If available, DNA from cancer patients was isolated from 
tumour tissue and leucocytes. Tumour biopsies were im- 
mediately frozen at - 20°C followed by homogenization, lysis, 
deproteinization and precipitation of DNA [14]. For DNA 
isolation from leucocytes, 20 ml of peripheral blood were taken 
in the presence of EDTA. Extraction was carried out using 
techniques described previously [21]. 
DNA (5 pg) was digested with EcoRI and partly with BarnHI, 
separated on 0.8% agarose gels and transferred to nitrocellulose 
filters by the Southern procedure [22]. Blots were hybridized to 
a ‘*P-labelled 2.6 kb EcoRI fragment [23] recognizing the 
3 ‘-end of the c-mos locus (fig. 1). The conditions were those of 
Maniatis et al. [24]. 
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3. RESULTS AND DISCUSSION I , 
Among the 140 EcoRI-digested DNA samples 
derived from unaffected individuals, five exhibited 
the presence of two fragments of 2.6 kb (Al) and 
5.6 kb (A2), while the other probes yielded only a 
single band of 2.6 kb (fig.1). RFLP analyses of the 
tumour patients resulted in the detection of allele 
A2 in six out of 156 investigated cases. This frag- 
ment was distributed among the different types of 
cancer (fig.2). The allele frequencies are listed in 
table 1. 
While the majority of DNA probes examined 
showed homozygosity for the 2.6 kb fragment, 
allele A2 appeared only in a heterozygote linkage 
with allele Al. The intensity of the fragments was 
in the ratio 1: 1 and no amplification of the 5.6 kb 
fragment, as has been observed in a pro-monocytic 
CM-S line [25], was detected. 
Fig.1. (A) Southern blot analysis of c-mos in EcoRI-digested 
DNA from three controls (lanes Kl-K3) after hybridization 
with the EcoRI fragment of the c-mos specific probe. (B) 
Hybridization of the same DNA samples after BarnHI 
digestion. (C) Restriction map of c-mos. Only those restriction 
sites which are useful for understanding of the present results 
are indicated. Restriction sites: E, EcoRI; B, BumHI; hH, A 
DNA digested with NindIII. 
tion of allele A2 between the sexes is striking. 
While four out of 60 normal male individuals 
(6.7%) carry an EcoRI polymorphism, only one 
Altogether the allele distribution between con- 
trol and tumour groups is comparable. Significant 
differences between specific types of tumours were 
not ascertainable (table 1). In all investigated 
cases, both normal and tumour tissue contained 
polymorphism when present. 
Table I 
Frequency (o/o) of the c-mos genotypes in tumour patients 
Al/Al Al /A2 
To determine the scope of the rearrangement 
responsible for the 5.6 kb fragment, probes 
generating two fragments were digested with 
BarnHI. Hybridization with the c-mos probe 
resulted in a single band of about 8.8 kb (fig. 1) ex- 
cluding a gross structural alteration of the c-mos 
locus. In view of previous studies [15,25], the 
5.6 kb fragment seems to be due to a base change. 
In contrast to the results of Lidereau et al. [15] 
we detected the EcoRI polymorphism even within 
the normal population. Nevertheless, the distribu- 
Controls 
(n = 140) 
Tumour patients 
(n = 156) 
Breast cancer 
(n = 75) 
Ovarian cancer 
(n = 46) 
Cervix cancer 
(n = 11) 
Uterus cancer 
(n = 9) 
Lymphomas 
(n = 15) 
96.4 3.6 
95.5 4.5 
97.3 2.7 
95.7 4.3 
90.9 9.1 
100.0 0.0 
93.3 6.7 
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Fig.2. RFLPs at the c-mos locus of tumour patients aftec digestion with EcoRI. DNA from: (A) two patients with breast cancer; (B) 
five patients with ovarian cancer; (C) five patients with lymphomas; (D) two patients with cervical cancer. XE, X DNA digested with 
EcoRI; hH, X DNA digested with HindIII; B, DNA from leucocytes of patients; T, DNA from tumour tissue of patients. 
DNA (1.25%) of the female population contains 
the 5.6 kb fragment. In this context, studies of the 
expression of mos in mice are worth mentioning. 
Depending on the course of development, distinct 
patterns of expression in female and male mouse 
germ cells have been observed and the transcripts 
differ from each other [26,27]. To what extent this 
suggested possible function of the murine mos 
gene in germ cell differentiation is connected with 
the occurrence of different allele frequencies be- 
tween the two sexes in man remains under con- 
sideration. 
As might be expected from previous studies 
[25,28] the EcoRI polymorphism is distributed 
among various kinds of tumours. Since the fre- 
quency of allele A2 is not significantly increased in 
tumour patients a general predisposition to 
malignancy seems to be unlikely. Reports of absent 
expression of c-mos in tumour tissue [4,29] sup- 
port this view. 
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